Echolight at Arab Health 2020
3 Januar 2020
Echolight obtains FDA clearence
23 Januar 2020
Show all

New important recognition for Echolight obtained from the European Key Opinion Leaders of ESCEO – European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

The Consensus Paper “Radiofrequency echographic multi‑spectrometry for the in‑vivo assessment of bone strength: state of the art—outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)” has recognized R.E.M.S. technology (Radiofrequency Echographic Multi Spectrometry) as innovative and effective method for the evaluation of bone health status. It represents a milestone in the medical innovation field for the assessment of bone strength, the diagnosis of osteoporosis and the risk of fracture.

R.E.M.S. technology goes beyond the limits of DXA, satisfying new clinical needs, as it is radiation-free, applicable to the spine and femur in subjects of any age, capable of early diagnosis of osteoporosis, predicting the risk of fracture and also obtaining a qualitative bone assessment.

The document quotes “R.E.M.S. represents the first clinically available method for direct non-ionizing measurement of lumbar and femoral BMD. Available scientific evidences describe R.E.M.S.-estimated BMD as an accurate diagnostic parameter, which resulted also a predictor of incident clinical fracture risk in a representative sample of female subjects. Moreover, R.E.M.S. has shown a further potential in the assessment of skeletal fragility based on bone structure quality through the Fragility Score parameter, which is independent from the densitometric evaluation.”

The recognition obtained from ESCEO is not only a goal, but an impulse towards the continuous evolution of technology aimed at the further improvement of the human health.

Read the document: click here

Es können keine Kommentare abgegeben werden.